



ANUH PHARMA LTD.

Registered Office : 3-A, Shivsagar Estate, North Wing,
Dr. Annie Besant Road, Worli, **MUMBAI - 400 018, INDIA.**
Tel. : +91-22-6622 7575 • Fax : +91-22-6622 7600 / 7500
E-Mail : anuh@sk1932.com • CIN: L24230MH1960PLC011586

Date: 08th August, 2025

To,
The Manager (Listing)
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort, Mumbai - 400 001

BSE Scrip Code: 506260

To,
Listing Compliance Department
National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1, G Block,
Bandra-Kurla Complex,
Bandra (E), Mumbai – 400051
NSE Symbol: ANUHPHR; Series: EQ

Subject: Outcome of Board Meeting dated, 08th August, 2025.

Dear Sir/Madam,

Pursuant to Regulation 30 and 33 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we wish to inform you that the Board of Directors of **Anuh Pharma Limited** (the Company) at its meeting held today, **Friday, 08th August, 2025**, has inter alia considered and approved the following:

1. The Un-Audited Financial Results along with Limited Review Report for the quarter ended 30th June, 2025 (annexed as **Annexure - A**);
2. Appointment of Mr. Vinayak Shenoy for the post of Chief Marketing Officer of the Company (annexed as **Annexure - B**).

The Meeting of the Board of Directors commenced at **12:30 p.m.** and concluded at **04:00 p.m.**

Further we would like to inform that book closure intimation will be done in due course.

Kindly take the above on your records.

Thanking you,

Yours faithfully,

FOR ANUH PHARMA LIMITED

MANAN VADHAN
COMPANY SECRETARY & COMPLIANCE OFFICER
Encl: a/a



ANUH PHARMA LTD.

CIN: L24230MH1960PLC011586

Regd. Office : 3-A, North Wing, Shivsagar Estate, Dr. Annie Besant Road, Worli, Mumbai - 400018

Tel: +91 22 6622 7575; Fax: +91 22 6622 7600; Email: anuh@sk1932.com; Website: www.anuhpharma.com

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE, 2025

(Rs. in Lakhs)

Sr. No.	Particulars	3 months ended 30/06/2025	3 months ended 31/03/2025	3 months ended 30/06/2024	12 months ended 31/03/2025
		Unaudited	Audited (Refer Note No.4)	Unaudited	Audited
(1)	(2)	(3)	(4)	(5)	(6)
I	Revenue from operations	18,647.94	19,813.95	13,790.83	66,151.49
II	Other income	338.84	139.83	371.91	945.53
III	Total Revenue (I + II)	18,986.78	19,953.78	14,162.74	67,097.02
IV	Expenses:				
	Cost of materials consumed	12,390.50	13,791.68	9,178.00	46,327.71
	Purchases of Stock-in-Trade	2,649.64	1,092.50	635.96	3,854.64
	Changes in inventories of finished goods, work-in-progress and Stock-in-Trade	222.26	(38.30)	706.07	(245.44)
	Employee benefits expense	629.79	684.62	513.60	2,303.92
	Finance costs	21.13	3.35	14.16	61.93
	Depreciation and amortization expense	251.50	275.60	188.00	873.94
	Other expenses	1,726.65	2,416.36	1,700.31	7,819.79
	Total expenses (IV)	17,891.47	18,225.81	12,936.10	60,996.49
V	Profit / (Loss) before exceptional and items and tax (III - IV)	1,095.31	1,727.97	1,226.64	6,100.53
VI	Exceptional items	-	-	-	-
VII	Profit / (Loss) before tax (V - VI)	1,095.31	1,727.97	1,226.64	6,100.53
VIII	Tax expenses:				
	(1) Current tax	249.00	484.00	266.00	1,467.00
	(2) Deferred tax	16.19	(59.29)	3.73	(165.22)
	(3) Income tax of earlier years	-	57.56	6.00	63.56
	Total Tax expenses (VIII)	265.19	482.27	275.73	1,365.34
IX	Profit/(Loss) after Tax (VII-VIII)	830.12	1,245.70	950.91	4,735.19
X	Other Comprehensive Income (net of Tax)				
	(i) Items that will not be reclassified to profit or loss	(6.07)	10.27	(5.94)	(1.70)
	(ii) Items that will be reclassified to profit or loss	-	-	-	-
	Total Other Comprehensive Income (net of Tax) (X)	(6.07)	10.27	(5.94)	(1.70)
XI	Total Comprehensive Income for the period (IX + X) (Comprising Profit / (Loss) and Other Comprehensive Income for the period)	824.05	1,255.97	944.97	4,733.49
	Paid up Equity Share Capital (Face value Rs. 5/- each)	2,505.60	2,505.60	2,505.60	2,505.60
	Other Equity (excluding revaluation reserves)	-	-	-	30,096.88
XII	Earnings per equity share (For respective periods) (In Rs.)				
	(1) Basic	1.66	2.49	1.90	9.45
	(2) Diluted	1.66	2.49	1.90	9.45
See accompanying notes to the financial results					



Notes:-

1. These unaudited financial results have been prepared in accordance with the recognition and measurement principles laid down in accordance with the Indian Accounting Standard (Ind AS) 34, "Interim Financial Reporting" as prescribed under Section 133 of the Companies Act 2013 ('the Act) read with the Companies (Indian Accounting Standards) Rules 2015, as amended from time to time, and other accounting principles generally accepted in India and in terms of Regulation 33 of the Securities Exchange Board of India ("SEBI") (Listing Obligations and Disclosure Requirements) Regulations 2015 (as amended).

2. These unaudited financial results for the quarter ended 30th June, 2025 were reviewed by the Audit Committee and approved by the Board of Directors at its respective meeting held on 08th August, 2025 in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and have been subjected to limited review by the Statutory Auditors of the Company.

3. Other Financial indicators

(Rs. in Lakhs)

Particulars	3 months ended 30/06/2025	3 months ended 31/03/2025	3 months ended 30/06/2024	12 months ended 31/03/2025
	Unaudited	Audited (Refer Note No.4)	Unaudited	Audited
EBITDA	1,367.94	2,006.92	1,428.81	7,036.40
% of EBITDA Margin	7.34	10.13	10.36	10.64
EBITDA (Adjusted to Forex (gain) / loss and Mark to Market (gain) / loss on Investment in Mutual funds)	1,143.16	2,152.09	1,250.86	6,821.55
% of Adjusted EBITDA Margin	6.13	10.86	9.07	10.31

4. The figures of the quarter ended 31st March, 2025 are the balancing figures between the audited figures in respect of the full financial year upto 31st March, 2025 and the unaudited published year to date figures upto 31st December, 2024 being the date of end of the third quarter of financial year respectively which were subject to limited review.

5. The Company has identified Bulk drug and Chemicals as its only primary reportable segment in accordance with the requirements of Ind AS 108, 'Operating Segments'. Accordingly, no-separate segment information has been provided.

6. Previous period's figures have been regrouped and reclassified, wherever necessary, to correspond with those of the current period.

For Anuh Pharma Ltd.



Ritesh Shah
Joint Managing Director
(DIN: 02496729)



Place : Mumbai

Date : 08th August, 2025

Independent Auditor's Review Report on the Quarterly Unaudited Financial Results of Anuh Pharma Limited (the "Company") Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

**TO THE BOARD OF DIRECTORS
Anuh Pharma Limited**

1. We have reviewed the accompanying statement of unaudited financial results of Anuh Pharma Limited (the "Company") for the quarter ended 30th June, 2025 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India (ICAI). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited financial results, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**PLACE: Mumbai
DATE: 08th August, 2025**



**For JAYANTILAL THAKKAR & CO.
CHARTERED ACCOUNTANTS
(FIRM REG. NO. 104133W)**

Dilip J. Thakkar

**DILIP J THAKKAR
PARTNER**

**MEMBERSHIP NO. 005369
UDIN: 25005369BMINPF5430**



ANUH PHARMA LTD.

Registered Office : 3-A, Shivsagar Estate, North Wing,
Dr. Annie Besant Road, Worli, **MUMBAI - 400 018, INDIA.**
Tel. : +91-22-6622 7575 • Fax : +91-22-6622 7600 / 7500
E-Mail : anuh@sk1932.com • CIN: L24230MH1960PLC011586

Annexure - B

BRIEF PROFILE OF MR. VINAYAK SHENOY - CHIEF MARKETING OFFICER

Sr. No.	PARTICULARS	PROFILE
1	Reason for change viz. Appointment, re-appointment resignation, removal, death or otherwise.	Appointment as Chief Marketing Officer.
2	Date of appointment /re-appointment / cessation (as applicable) and terms of appointment	Appointment w.e.f. 11 th August, 2025 on the terms mentioned in the letter of appointment.
3	Brief Profile (in case of appointment)	Mr. Vinayak Shenoy, a seasoned Business Development and Sales professional with over 15 years of experience in APIs and Intermediates, managing global markets including the USA, Europe, CIS, SEA, LATAM, and India. Proven expertise in key account management, market-entry strategies, and leading customer-centric teams to drive consistent business growth. Skilled in navigating cross-functional challenges across supply chain, regulatory, and quality functions to deliver value and customer satisfaction. Recognized for a proactive, goal-driven approach and strong global business acumen.
4	Disclosure of Relationships between Directors (in case of appointment of Director)	Not applicable

FOR ANUH PHARMA LIMITED

MANAN VADHAN
COMPANY SECRETARY AND COMPLIANCE OFFICER

